Bagri, Narendra KumarKumar, SathishRamanan, Athimalaipet V2023-08-252023-08-252022-12Bagri Narendra Kumar, Kumar Sathish, Ramanan Athimalaipet V. Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward. Indian Pediatrics. 2022 Dec; 59(12): 913-9150079-60610974-7559http://imsear.searo.who.int/handle/123456789/225274The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.BiosimilarRheumatic diseasesSafetyJournal ArticleIndiaDivision of Pediatric Rheumatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, IndiaPediatric Rheumatology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, IndiaPaediatric Rheumatology, Bristol Royal Hospital for Children and Translational Health Sciences, University of Bristol, Upper Maudlin Street, Bristol, BS2 8BJ, United Kingdom.